Der Kaninchen Polyklonal anti-GP5 Antikörper wird verwendet zum Nachweis von GP5 in Proben von Maus, Human und Ratte. Er wurde validiert für WB, FACS, IHC, ELISA und IF.
GP5
Reaktivität: Human
WB, ELISA
Wirt: Maus
Monoclonal
unconjugated
Applikationshinweise
Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-1:2000,IHC: 1:100-1:300,ELISA 1:10000,IF 1:50-200
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
Liquid in PBS containing 50 % glycerol, 0.5 % BSA and 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C
Informationen zur Lagerung
Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Haltbarkeit
12 months
Target
GP5
(Glycoprotein V (Platelet) (GP5))
Andere Bezeichnung
CD42d
Hintergrund
GP5, Platelet glycoprotein V, GPV, Glycoprotein 5, CD42dHuman platelet glycoprotein V (GP5) is a part of the Ib-V-IX system of surface glycoproteins that constitute the receptor for von Willebrand factor (VWF, MIM 613160) and mediate the adhesion of platelets to injured vascular surfaces in the arterial circulation, a critical initiating event in hemostasis. The main portion of the receptor is a heterodimer composed of 2 polypeptide chains, an alpha chain (GP1BA, MIM 606672) and a beta chain (GP1BB, MIM 138720), that are linked by disulfide bonds. The complete receptor complex includes noncovalent association of the alpha and beta subunits with platelet glycoprotein IX (GP9, MIM 173515) and GP5. Mutations in GP1BA, GP1BB, and GP9 have been shown to cause Bernard-Soulier syndrome (MIM 231200), a bleeding disorder (review by Lopez et al. 1998 [PubMed: 9616133]).